BCDA
BiocardiaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BCDA Profile
Biocardia, Inc.
A clinical-stage biotechnology company developing innovative cardiovascular therapies, including cell-based treatments for heart failure
Biological Technology
01/12/1994
08/02/2019
NASDAQ Stock Exchange
17
12-31
Common stock
320 Soquel Way, Sunnyvale, California 94085
--
Biocardia, Inc., was incorporated in Delaware on January 12, 1994. The company is a clinical-stage regenerative medicine company developing novel therapies for cardiovascular diseases with significant unmet medical needs. The company's primary therapeutic candidate is the CardiAMP cell therapy system under development, which provides autologous bone marrow-derived cell therapy for the treatment of two clinical indications: heart failure that occurs after a heart attack and chronic myocardial ischemia.
